Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds

Condition(s) targeted: Local Pain; Chronic Wounds

Intervention: Morphine gel (Drug); Neutral gel (Other)

Phase: Phase 3

Status: Recruiting

Sponsored by: Institut Curie

Official(s) and/or principal investigator(s):
Carole Bouleuc, MD, Principal Investigator, Affiliation: Institut Curie - Hôpital René Huguenin
Audrey Hurgon, MD, Study Director, Affiliation: Institut Curie Paris

Overall contact:
Patricia TRESCA, Leader, Phone: 33156245630, Email: patricia.tresca@curie.fr

This phase III study aims to show that topical morphine low doses treats localized pain in chronic wounds, intense and rebellious to systemic analgesics included or not opioids.

Official title: Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg for the last 72 hours of the study

Secondary outcome:

Reduction in average daily pain intensity score on a numerical rating scale self assessment, measured on an 11-point between day 1 and day 11

Evaluate the percentage of local pain relief for 24 hours on a rating scale from 0 to 100%

Assess and characterize the evolution of local pain on a global impression scale change : Pain related Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC)

Assess patient satisfaction with treatment of local pain (score 0-4)

Evaluate the impact score of local pain on sleep (self-report scale of 0 to 100%)

Determine the time (in hours) before using oral immediate-release morphine after application of local treatment

Determination of cumulative dose of oral immediate-release morphine (in milligrams) of the 11 days of treatment for relieving painful access of local origin

Evaluate systemic and local side effects of analgesic treatment (incidence, severity and location)

Evaluate the systemic absorption of topical morphine blood test after the first application

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female, aged over 18 years

- Painful chronic wounds (bedsores, wound tumor, arterial ulcers, venous or mixed

diabetic ulcer if systolic pressure index >0. 8, necrotic angiodermatitis not graftable), a bottom surface 300 cm² and does not require more than 15 ml of gel by application. When patient has multiple painful chronic wounds, the wound having only the highest pain intensity is considered for evaluation.

- Ineffective systemic analgesic with or without opioid analgesic established and

maintained at the same dose for 3 days before inclusion. If treatment includes morphine, the daily dose should not exceed 60 mg of morphine equivalent and this treatment must be a treatment exclusive background.

- Patient requiring an analgesic equilibration for intense and rebellious local pain,

with a daily average score greater than or equal to 5, on a graduated numerical scale of 0 to 10. The score is defined at the inclusion and corresponds to the pain intensity felt locally by the patient under treatment systemic analgesic with or without co-analgesics.

- If analgesics to treat systemic pain is ongoing, it must have been introduced for

more than 3 days (according to criteria 3)

- If antidepressant treatment is in progress, it must have been established for over a

month for a tricyclic and for more than 15 days for other classes of antidepressants.

- If an anti-epileptic treatment analgesic is in progress, it must have been

established for over 15 days.

- Signing of the informed consent form.

- Patient able to respond the self-assessment questionnaires (sufficient understanding

assessments, proficiency in French).

- Patient affiliated to an health insurance plan

Exclusion Criteria:

- Allergy to morphine or carboxymethylcellulose or history of intolerance to morphine

- Analgesic at baseline including systemic morphine to greater than 60 mg equivalent

dose of morphine treatment

- Fistulated wound

- Heavily exuding wound

- Wound bleeding (spontaneous bleeding)

- Ongoing radiotherapy on chronic wound

- Creatinine > 110 µmol/L, Total bilirubin > 20 µmol/L

- Not communicating patient

- Unable to comply with requirement of the protocol (11 days)

- Patient pregnant or of childbearing age without contraceptive therapy or lactating

- Person deprived of liberty or under guardianship

- Only for pharmacokinetic analysis: analgesics at baseline including morphine or

hydromorphone or oxycodone or codeine. Fentanyl is allowed

Patricia TRESCA, Leader, Phone: 33156245630, Email: patricia.tresca@curie.fr

Hôpital Louis Mourier, Colombes, Ile de France 92700, France; Not yet recruiting
Philippe Charru, MD
Philippe Charru, MD, Principal Investigator

Groupe Hospitalier Bichat, Paris, Ile de France 75877, France; Not yet recruiting
Nathalie Faucher, MD
Nathalie Faucher, MD, Principal Investigator

Hôpital Jean-Jaurès, Paris, Ile de France 75019, France; Recruiting
Julia Revnic, MD
Julia Revnic, MD, Principal Investigator

Institut Curie, Paris, Ile de France 75005, France; Recruiting
Irène KRIEGEL, MD, Email: irene.kriegel@curie.fr
Irène Kriegel, MD, Principal Investigator

Institut Curie - Hôpital René Huguenin, Saint-Cloud, Ile de France 92210, France; Recruiting
Valérie Triolaire, MD, Phone: 33147111515, Email: valerie.triolaire@curie.fr
Valérie Triolaire, MD, Principal Investigator

Starting date: April 2014
Last updated: September 5, 2014